Edition:
United Kingdom

MabVax Therapeutics Holdings Inc (MBVX.OQ)

MBVX.OQ on NASDAQ Stock Exchange Capital Market

0.86USD
12 Dec 2017
Change (% chg)

$-0.07 (-7.87%)
Prev Close
$0.93
Open
$0.90
Day's High
$0.92
Day's Low
$0.84
Volume
45,229
Avg. Vol
69,272
52-wk High
$3.97
52-wk Low
$0.43

Latest Key Developments (Source: Significant Developments)

MabVax Therapeutics files for resale of 9.7 mln shares‍​
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - MabVax Therapeutics Holdings Inc : :MabVax Therapeutics Holdings Inc - files for resale of 9.7 million shares of common stock of co by certain stockholders ‍​.  Full Article

MabVax Therapeutics files for resale of up to 6.97 mln shares of co's common stock‍​
Thursday, 19 Oct 2017 

Oct 20 (Reuters) - MabVax Therapeutics Holdings Inc :MabVax Therapeutics Holdings Inc files for resale of up to 6.97 million shares of co's common stock‍​ by the selling stockholders - SEC filing‍​.  Full Article

Mabvax Therapeutics starts patient enrollment in phase 1 trial for cancer drug MVT-1075
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Mabvax Therapeutics Holdings Inc :Mabvax Therapeutics initiates patient enrollment in a phase 1 trial for MVT-1075, a new radioimmunotherapy treatment for advanced pancreatic, colon and lung cancers.Mabvax Therapeutics Holdings Inc - ‍Plans to announce topline interim results before year end from study​.  Full Article

MabVax stockholders approve remaining proposal at stockholders meeting
Saturday, 7 Oct 2017 

Oct 6 (Reuters) - MabVax Therapeutics Holdings Inc :MabVax Therapeutics Holdings - ‍resolution approved to implement, if necessary a reverse stock split of company's issued and outstanding common stock​.MabVax Therapeutics Holdings Inc - ‍ implementation of reverse stock split stock by a ratio of not less than 1 -for-2 and not more than 1 -for-20.  Full Article

MabVax Therapeutics expands patient enrollment in phase I trial for treatment of pancreatic cancer
Tuesday, 7 Jun 2016 

Mabvax Therapeutics Holdings Inc :MabVax therapeutics expands patient enrollment in phase I trial for treatment of pancreatic cancer to Memorial Sloan Kettering Cancer Center.  Full Article

BRIEF-MabVax Therapeutics Holdings Files For Offering Of Up To 2.7 Mln Shares - SEC Filing

* MABVAX THERAPEUTICS HOLDINGS INC FILES FOR COMMON STOCK OFFERING OF UP TO 2.7 MILLION SHARES - SEC FILING Source text: (http://bit.ly/2kom2gh) Further company coverage: